Chemo - Recurrent

Question 1

Olaparib maintenance 400mg capsule bid: after response to chemo for at least 2nd recurrence:
Study 19 - Lederman:

Typical side efects, time frame and discontinuation rate:

Answer 1

N/V
anemia
fatigue/asthenia - similar to placebo

Rarely for new common AE p 6m

6% olaparib pts stopped tx due to AE vs. 2% placebo

Question 2

Olaparib maintenance 400mg capsule bid: after response to chemo for at least 2nd recurrence:
Study 19 - Lederman

How often were patients receiving olaparib - at 2 & 6 years from randomization?

Answer 2

25% pts at 2y

10% at 6y

Question 3

CMS criteria for quality Oncology care per incentive programs?

Answer 3

Deaths within 14 days of chemo and 30 days of ICU admission

<3 days hospice stay b death

Question 4

Thermal ablation for 🔄 oligometastatic ovarian cancer: UCLA 2001-2019: 42🙋‍♀️/119 🦀: primary and secondary efficacy, local PFS?

Answer 4

primary efficacy: 96%

secondary efficacy: 80%: 4/5

local PFS: 17 months (median f/u 10 m)

Question 5

phII of cediranib 30”qD (TKi) and olaparib 200”bid in rOvCa vs. olaparib 400” bid: PFS ~ BRCA status?

Answer 5

wt or unknown BRCA:
17 vs 6 m p=0.008

mBRCA:
17 vs 19m not ss

But phIII NRG-GY004 shown no difference between CT and combination of cediranib-olaparib with PFS of 10m

Question 6

Platinum sensitive rEOC: phIII AVANOVA2: Niraparib 300”qD +/- Bev 15mg/kg IV q21d: PFS?

Answer 6

11 vs. 6m

w/ greater benefit in wtBRCA and platinum free interval < 12 m

Question 7

Active agents in OvCa: (13)

Answer 7

Alkylating agents
Bevacizumab
Hexamethylamine
Doxorubicin
Cisplatin/Carbo
5-FU
MTX
Etoposide
Vinorelbine
Gemcitabine
Topotecan
Liposomal doxorubicin
Docetaxel

Question 8

Oligometastasis while on PARPi, 75% scenario. What to do?

Answer 8

Resect or XRT and continue with PARPi